drugset / Trial / NCT02545361
Safety, Tolerability, and Anti-cancer Activity of KAHR-102 (The Study Drug) for the Treatment of Lymphoma Patients
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and to determine the Dose Limiting Toxicity (DLT) and the Maximal Tolerated Dose (MTD) of KAHR-102.
Timeline
- Start
- 2018-04
- Primary completion
- 2020-04
- Completion
- 2020-04
Outcome
Outcome not reported
Stopped: “Program de-prioritized”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KAHR-102 | Protein / enzyme biologic | 2 ug/kg | Subcutaneous |
| Subject | KAHR-102 | Protein / enzyme biologic | 4 ug/kg | Subcutaneous |
| Subject | KAHR-102 | Protein / enzyme biologic | 8 ug/kg | Subcutaneous |
| Subject | KAHR-102 | Protein / enzyme biologic | 12 ug/kg | Subcutaneous |